NewcelX Ltd. (NCEL)
NASDAQ: NCEL · Real-Time Price · USD
5.14
-2.15 (-29.49%)
At close: Nov 3, 2025, 4:00 PM EST
5.04
-0.10 (-1.95%)
After-hours: Nov 3, 2025, 7:59 PM EST
NewcelX Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
23.18M USD
Revenue Chart
* This company reports financials in ILS.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
NCEL News
- 15 hours ago - NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd. - PRNewsWire